Correlation Between Corvus Pharmaceuticals and Ikena Oncology

Can any of the company-specific risk be diversified away by investing in both Corvus Pharmaceuticals and Ikena Oncology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Corvus Pharmaceuticals and Ikena Oncology into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Corvus Pharmaceuticals and Ikena Oncology, you can compare the effects of market volatilities on Corvus Pharmaceuticals and Ikena Oncology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Corvus Pharmaceuticals with a short position of Ikena Oncology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Corvus Pharmaceuticals and Ikena Oncology.

Diversification Opportunities for Corvus Pharmaceuticals and Ikena Oncology

0.81

Correlation Coefficient

Corvus Pharmaceuticals  Ikena Oncology

Very poor diversification

The 3 months correlation between Corvus and Ikena is 0.81. Overlapping area represents the amount of risk that can be diversified away by holding Corvus Pharmaceuticals and Ikena Oncology in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Ikena Oncology and Corvus Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Corvus Pharmaceuticals are associated (or correlated) with Ikena Oncology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Ikena Oncology has no effect on the direction of Corvus Pharmaceuticals i.e., Corvus Pharmaceuticals and Ikena Oncology go up and down completely randomly.

Pair Corralation between Corvus Pharmaceuticals and Ikena Oncology

Given the investment horizon of 90 days Corvus Pharmaceuticals is expected to under-perform the Ikena Oncology. In addition to that, Corvus Pharmaceuticals is 1.87 times more volatile than Ikena Oncology. It trades about -0.15 of its total potential returns per unit of risk. Ikena Oncology is currently generating about -0.13 per unit of volatility. If you would invest  160.00  in Ikena Oncology on December 28, 2024 and sell it today you would lose (28.00) from holding Ikena Oncology or give up 17.5% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Strong
Accuracy	100.0%
Values	Daily Returns

Corvus Pharmaceuticals  vs.  Ikena Oncology

Corvus Pharmaceuticals

Risk-Adjusted Performance

Very Weak

Over the last 90 days Corvus Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Ikena Oncology

Risk-Adjusted Performance

Very Weak

Over the last 90 days Ikena Oncology has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Corvus Pharmaceuticals and Ikena Oncology

The main advantage of trading using opposite Corvus Pharmaceuticals and Ikena Oncology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Corvus Pharmaceuticals position performs unexpectedly, Ikena Oncology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ikena Oncology will offset losses from the drop in Ikena Oncology's long position.

The idea behind Corvus Pharmaceuticals and Ikena Oncology pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.